NCT00102856

Neuromodulation and Language Acquisition (Stage Ib)

Neuromodulation and Language Acquisition (KS-Neuromod_01, Stage Ib)

• Status: Suspended
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (planned)
• Sponsor: University Hospital Muenster · Academic / Other
• Sex: All
• Age: 20 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects.

Detailed description

Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether a selective d2/d3 dopamine agonist (pramipexole) or cholinergic neuromodulation (rivastigmine), after a titration period of five days, will yield a learning enhancement comparable to using levodopa in healthy subjects. The expected scientific results will strengthen the basis for transferring neuromodulatory interventions from the laboratory to stroke patients with language dysfunctions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Pramipexole
DRUG	Rivastigmine

Timeline

• Start date: 2005-01-01
• Completion: 2006-06-01
• First posted: 2005-02-04
• Last updated: 2010-06-24

Locations

1 site across 1 country: Germany